Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

669 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques.
Magnani DM, Rogers TF, Beutler N, Ricciardi MJ, Bailey VK, Gonzalez-Nieto L, Briney B, Sok D, Le K, Strubel A, Gutman MJ, Pedreño-Lopez N, Grubaugh ND, Silveira CGT, Maxwell HS, Domingues A, Martins MA, Lee DE, Okwuazi EE, Jean S, Strobert EA, Chahroudi A, Silvestri G, Vanderford TH, Kallas EG, Desrosiers RC, Bonaldo MC, Whitehead SS, Burton DR, Watkins DI. Magnani DM, et al. Among authors: burton dr. Sci Transl Med. 2017 Oct 4;9(410):eaan8184. doi: 10.1126/scitranslmed.aan8184. Sci Transl Med. 2017. PMID: 28978754 Free PMC article.
Antibodies in human infectious disease.
Parren PW, Poignard P, Ditzel HJ, Williamson RA, Burton DR. Parren PW, et al. Among authors: burton dr. Immunol Res. 2000;21(2-3):265-78. doi: 10.1385/IR:21:2-3:265. Immunol Res. 2000. PMID: 10852127 Review.
Antibodies, viruses and vaccines.
Burton DR. Burton DR. Nat Rev Immunol. 2002 Sep;2(9):706-13. doi: 10.1038/nri891. Nat Rev Immunol. 2002. PMID: 12209139 Review.
Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.
Mascola JR, Lewis MG, VanCott TC, Stiegler G, Katinger H, Seaman M, Beaudry K, Barouch DH, Korioth-Schmitz B, Krivulka G, Sambor A, Welcher B, Douek DC, Montefiori DC, Shiver JW, Poignard P, Burton DR, Letvin NL. Mascola JR, et al. Among authors: burton dr. J Virol. 2003 Oct;77(19):10348-56. doi: 10.1128/jvi.77.19.10348-10356.2003. J Virol. 2003. PMID: 12970419 Free PMC article.
Public health. A sound rationale needed for phase III HIV-1 vaccine trials.
Burton DR, Desrosiers RC, Doms RW, Feinberg MB, Gallo RC, Hahn B, Hoxie JA, Hunter E, Korber B, Landay A, Lederman MM, Lieberman J, McCune JM, Moore JP, Nathanson N, Picker L, Richman D, Rinaldo C, Stevenson M, Watkins DI, Wolinsky SM, Zack JA. Burton DR, et al. Science. 2004 Jan 16;303(5656):316. doi: 10.1126/science.1094620. Science. 2004. PMID: 14726576 No abstract available.
HIV vaccine design and the neutralizing antibody problem.
Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT. Burton DR, et al. Nat Immunol. 2004 Mar;5(3):233-6. doi: 10.1038/ni0304-233. Nat Immunol. 2004. PMID: 14985706 No abstract available.
669 results